Maximilien Baas-Thomas, Ph.D. brings experience across scientific research, management consulting, and startup leadership, with a focus on business development, strategic partnerships, and commercialization in life sciences. Before joining BioVergence, he was Director of Strategy & Operations at Envoya, Inc., where he built the gene-delivery startup’s partnership function from the ground up, co-led collaboration negotiations through signing, and closed the company’s first revenue-generating agreement with a global pharmaceutical partner. Earlier, as a management consultant at the Boston Consulting Group, he advised pharmaceutical, healthcare, and technology clients on distribution strategy, clinical program acceleration, and go-to-market. He holds a Ph.D. in Genetics & Genomics from Harvard University, completed in the George Church lab, where his work on megabase-scale genome synthesis and recoding was published in Nature and other leading journals, and a B.S. in Biology from MIT.

At BioVergence, Max supports business development, building strategic partnerships across capital markets, life sciences, and commercialization to expand access to non-dilutive capital for biopharma innovators.